Zelira Therapeutics (ASX:ZLD) Long-Term Capital Lease Obligation : A$0.00 Mil (As of Dec. 2023)

View and export this data going back to 2003. Start your Free Trial

What is Zelira Therapeutics Long-Term Capital Lease Obligation?

Zelira Therapeutics's Long-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was A$0.00 Mil.

Zelira Therapeutics's quarterly Long-Term Capital Lease Obligation increased from Dec. 2022 (A$0.00 Mil) to Jun. 2023 (A$0.30 Mil) but then declined from Jun. 2023 (A$0.30 Mil) to Dec. 2023 (A$0.00 Mil).

Zelira Therapeutics's annual Long-Term Capital Lease Obligation declined from Jun. 2021 (A$0.46 Mil) to Jun. 2022 (A$0.38 Mil) and declined from Jun. 2022 (A$0.38 Mil) to Jun. 2023 (A$0.30 Mil).

Zelira Therapeutics Long-Term Capital Lease Obligation Historical Data

The historical data trend for Zelira Therapeutics's Long-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zelira Therapeutics Long-Term Capital Lease Obligation Chart

Zelira Therapeutics Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Long-Term Capital Lease Obligation

Get a 7-Day Free Trial

0.57

0.46

0.38

0.30

Zelira Therapeutics Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Long-Term Capital Lease Obligation	Get a 7-Day Free Trial															-	0.38	-	0.30	-

Zelira Therapeutics (ASX:ZLD) Long-Term Capital Lease Obligation Explanation

Long-Term Capital Lease Obligation are the amount due for long-term asset lease agreements that are nearly equivalent to asset purchases. Capital lease obligations are installment payments that constitute a payment of principal plus interest for the capital lease. The Short-Term Capital Lease Obligation is the portion of a Long-Term Capital Lease Obligation that is due over the next year.

Under US Generally Accepted Accounting Principles (GAAP), a capital lease is essentially equivalent to a purchase by the lessee if it meets the following criteria:

1. Ownership of the asset is transferred to the lessee at the end of the lease term;
2. The lease contains a bargain purchase option to buy the equipment at less than fair market value;
3. The lease term equals or exceeds 75% of the asset's estimated useful life;
4. The present value of the lease payments equals or exceeds 90% of the total original cost of the equipment.

Zelira Therapeutics Long-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Zelira Therapeutics's Long-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Zelira Therapeutics (ASX:ZLD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Zelira Therapeutics Ltd (ASX:ZLD) » Definitions » Long-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ZLDAF:USA G1G:Germany

Address

101 St George’s Terrace, Level 3, Perth, WA, AUS, 6000

Website

https://www.zeliratx.com

Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.

Zelira Therapeutics (ASX:ZLD) Headlines

No Headlines